News

Filter

Current filters:

ArQule

Daiichi Sankyo returns rights to ArQule for global AKT program

03-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has returned worldwide rights for the development and…

ARQ 092ARQ 197ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearchtivantinib

Another disappointment with Daiichi Sankyo and ArQule's tivantinib

14-01-2013

US drug developer ArQule (Nasdaq: ARQL) saw its shares plunge 23% to $2.25 in premarket trading on Friday,…

ArQuleDaiichi SankyoOncologyPharmaceuticalResearchtivantinib

ArQule and Daiichi Sankyo drop tivantinib trial in NSCLC

03-10-2012

USA-based drug developer ArQule (Nasdaq: ARQL) saw its shares plunge 62% to $1.90 after, along with its…

ArQuleBiotechnologyDaiichi SankyoOncologyPharmaceuticalResearchtivantinib

Daiichi Sankyo to license ARQ 092 from ArQule, under joint AKIP research collaboration

11-11-2011

Japanese drug major Daiichi Sankyo (TSE 4568) says it has executed a license agreement with USA-based…

ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearch

Kyowa Hakko Kirin starts Ph III trial of ARQ 197 (tivantinib) in NSCLC patients in Asia

10-08-2011

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says it has initiated an international Phase III clinical…

ArQuleKyowa Hakko KirinOncologyPharmaceuticalResearchtivantinib

ArQule and Daiichi Sankyo move NSCLC drug ARQ 197 into Phase III clinical trial plan

04-08-2010

USA-based ArQule and Japanese drug major Daiichi Sankyo say they will move forward with a Phase III clinical…

ArQuleDaiichi SankyoOncologyPharmaceuticalResearch

COMPANY SPOTLIGHT

Menarini

Back to top